logo
Science Portal
Copyright © Médecins Sans Frontières
v2.1.5209.produseast1
About MSF Science Portal
About
Contact Us
Frequently Asked Questions (FAQs)
Privacy Policy
Terms of Use
Copyright © Médecins Sans Frontières
v2.1.5209.produseast1
Showing 1 - 9 of 9 Items
Showing 1 - 9 of 9 Items
Sort By: Relevance
  • Newest to oldest
  • Oldest to newest
  • Relevance
Journal Article
|
Research

Combination Treatment for Visceral Leishmaniasis Patients Co-infected with Human Immunodeficiency Virus in India

Mahajan R, Das P, Isaakidis P, Sunyoto T, Sagili KD,  et al.
2015-06-30 • Clinical Infectious Diseases
2015-06-30 • Clinical Infectious Diseases
There are considerable numbers of patients co-infected with Human Immunodeficiency Virus (HIV) and Visceral Leishmaniasis (VL) in the VL-endemic areas of Bihar, India. These patients are...
Journal Article
|
Research

Visceral leishmaniasis and HIV co-infection in Bihar, India: long-term effectiveness and treatment outcomes with liposomal amphotericin B (AmBisome)

Burza S, Mahajan R, Singh A, van Griensven J, Pandey K,  et al.
2014-08-07 • PLOS Neglected Tropical Diseases
2014-08-07 • PLOS Neglected Tropical Diseases
Visceral Leishmaniasis (VL; also known as kala-azar) is an ultimately fatal disease endemic in the Indian state of Bihar, while HIV/AIDS is an emerging disease in this region. A 2011 obs...
Journal Article
|
Research

HIV and visceral leishmaniasis coinfection in Bihar, India: an underrecognized and underdiagnosed threat against elimination

Burza S, Mahajan R, Sanz MG, Sunyoto T, Kumar R,  et al.
2014-05-10 • Clinical Infectious Diseases
2014-05-10 • Clinical Infectious Diseases
Although human immunodeficiency virus (HIV) and visceral leishmaniasis coinfection is recognized as a major public health challenge in Africa, data regarding the prevalence in India are ...
Journal Article
|
Research

Five-year field results and long-term effectiveness of 20 mg/kg liposomal amphotericin B (Ambisome) for visceral leishmaniasis in Bihar, India

Burza S, Sinha PK, Mahajan R, Lima MA, Mitra G,  et al.
2014-01-02 • PLOS Neglected Tropical Diseases
2014-01-02 • PLOS Neglected Tropical Diseases
Visceral Leishmaniasis (VL; also known as Kala-azar) is an ultimately fatal disease endemic in Bihar. A 2007 observational cohort study in Bihar of 251 patients with VL treated with 20 m...
Journal Article
|
Research

Risk factors for visceral leishmaniasis relapse in immunocompetent patients following treatment with 20 mg/kg liposomal amphotericin B (Ambisome) in Bihar, India

Burza S, Sinha PK, Mahajan R, Lima MA, Mitra G,  et al.
2014-01-02 • PLOS Neglected Tropical Diseases
2014-01-02 • PLOS Neglected Tropical Diseases
A proportion of all immunocompetent patients treated for visceral leishmaniasis (VL) are known to relapse; however, the risk factors for relapse are not well understood. With the support...
Journal Article
|
Letter

One-year follow-up of immunocompetent male patients treated with miltefosine for primary visceral leishmaniasis in Bihar, India

Burza S, Nabi E, Mahajan R, Mitra G, Lima MA
2013-11-01 • Clinical Infectious Diseases
2013-11-01 • Clinical Infectious Diseases
Journal Article
|
Research

Liposomal amphotericin B for visceral leishmaniasis in human immunodeficiency virus-coinfected patients: 2-year treatment outcomes in Bihar, India

Sinha PK, van Griensven J, Pandey K, Kumar N, Verma N,  et al.
2011-10-01 • Clinical Infectious Diseases
2011-10-01 • Clinical Infectious Diseases
Reports on treatment outcomes of visceral leishmaniasis (VL)-human immunodeficiency virus (HIV) coinfection in India are lacking. To our knowledge, none have studied the efficacy of lipo...
Journal Article
|
Research

Post kala-azar dermal leishmaniasis following treatment with 20 mg/kg liposomal amphotericin B (Ambisome) for primary visceral leishmaniasis in Bihar, India

Burza S, Sinha PK, Mahajan R, Gonzalez Sanz M, Lima MA,  et al.
2014-01-02 • PLOS Neglected Tropical Diseases
2014-01-02 • PLOS Neglected Tropical Diseases
The skin disorder Post Kala-Azar Dermal Leishmaniasis (PKDL) occurs in up to 10% of patients treated for visceral leishmaniasis (VL) in India. The pathogenesis of PKDL is not yet fully u...
Journal Article
|
Research

Effectiveness and safety of liposomal amphotericin B for visceral leishmaniasis under routine program conditions in Bihar, India

Sinha PK, Roddy P, Palma PP, Kociejowski A, Lima MA,  et al.
2010-08-01 • American Journal of Tropical Medicine and Hygiene
2010-08-01 • American Journal of Tropical Medicine and Hygiene
We evaluated, through the prospective monitoring of 251 patients at Sadar Hospital in Bihar, India, the effectiveness and safety of 20 mg/kg body weight of liposomal amphotericin B for t...